Oregon Public Employees Retirement Fund maintained its stake in Zoetis Inc. (NYSE:ZTS) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 51,672 shares of the company’s stock at the end of the second quarter. Oregon Public Employees Retirement Fund’s holdings in Zoetis were worth $3,223,000 at the end of the most recent quarter.
Other large investors have also added to or reduced their stakes in the company. Assetmark Inc. boosted its position in shares of Zoetis by 4.6% in the first quarter. Assetmark Inc. now owns 1,918 shares of the company’s stock valued at $102,000 after buying an additional 85 shares during the last quarter. Guardian Life Insurance Co. of America boosted its position in shares of Zoetis by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock valued at $102,000 after buying an additional 13 shares during the last quarter. Point72 Asia Hong Kong Ltd purchased a new position in shares of Zoetis during the first quarter valued at about $111,000. Advisory Services Network LLC purchased a new position in shares of Zoetis during the first quarter valued at about $112,000. Finally, First Interstate Bank boosted its position in shares of Zoetis by 3.5% in the first quarter. First Interstate Bank now owns 2,250 shares of the company’s stock valued at $120,000 after buying an additional 76 shares during the last quarter. 92.70% of the stock is currently owned by institutional investors.
Shares of Zoetis Inc. (NYSE ZTS) traded down 0.25% during mid-day trading on Friday, reaching $60.75. The company had a trading volume of 1,513,092 shares. The company has a market capitalization of $29.71 billion, a price-to-earnings ratio of 34.34 and a beta of 1.02. Zoetis Inc. has a 52 week low of $46.86 and a 52 week high of $63.85. The stock has a 50 day moving average of $62.00 and a 200-day moving average of $58.20.
Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.53. The company had revenue of $1.27 billion for the quarter, compared to the consensus estimate of $1.27 billion. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. Zoetis’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.49 earnings per share. On average, analysts expect that Zoetis Inc. will post $2.34 earnings per share for the current fiscal year.
Several research analysts have issued reports on ZTS shares. Zacks Investment Research raised Zoetis from a “hold” rating to a “buy” rating and set a $67.00 target price on the stock in a research report on Wednesday, May 10th. Jefferies Group LLC raised their target price on Zoetis from $65.00 to $70.00 and gave the stock a “buy” rating in a research report on Tuesday, May 9th. BMO Capital Markets reissued a “buy” rating and issued a $60.00 target price on shares of Zoetis in a research report on Thursday, May 4th. Argus reissued a “buy” rating and issued a $69.00 target price (up from $60.00) on shares of Zoetis in a research report on Tuesday, May 30th. Finally, CL King assumed coverage on Zoetis in a research report on Friday, May 26th. They issued a “buy” rating and a $71.00 target price on the stock. One analyst has rated the stock with a sell rating, five have given a hold rating and twelve have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $64.78.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.